

LIBERIA PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia			
2. Grant Number: 1115-LBR-04a-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 19 August 2013			
5. Programme Title: NVS, Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2008 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2008-2014	2015	Total ²
Programme Budget (US\$)	US\$9,126,127 ³	US\$505,000	US\$9,631,127
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2008-2014	2015	
Number of Pentavalent vaccines doses		247,300	
Number of AD syringes		278,600	
Number of safety boxes		3,075	
Annual Amounts (US\$)	US\$9,126,127 ⁵	US\$505,000	
12. Procurement agency: UNICEF			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.


³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable.	
14. Co-financing obligations: Reference code: 1115-LBR-04a-X-C	
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	27,900
Value of vaccine doses (US\$)	US\$53,212
Total Co-Financing Payments (US\$) (including freight)	US\$55,500
15. Operational support for campaigns: Not applicable	
16. Additional documents to be delivered for future disbursements:	
Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent.	15 May 2015
17. Financial Clarifications: Not applicable	
18. Other conditions: Not applicable.	

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

LIBERIA PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia			
2. Grant Number: 1315-LBR-12c-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 19 August 2013			
5. Programme Title: NVS, Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2014 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2014	2015	Total ²
Programme Budget (US\$)	US\$2,988,500 ³	US\$1,313,500	US\$4,302,000
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2014	2015	
Number of Pneumococcal vaccines doses		309,600	
Number of AD syringes		337,700	
Number of safety boxes		3,725	
Annual Amounts (US\$)	US\$2,988,500 ⁵	US\$1,313,500	
12. Procurement agency: UNICEF			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable.									
<p>14. Co-financing obligations: Reference code: 1315-LBR-12c-X-C According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>19,800</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$62,194</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$66,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	19,800	Value of vaccine doses (US\$)	US\$62,194	Total Co-Financing Payments (US\$) (including freight)	US\$66,000
Type of supplies to be purchased with Country funds in each year	2015								
Number of vaccine doses	19,800								
Value of vaccine doses (US\$)	US\$62,194								
Total Co-Financing Payments (US\$) (including freight)	US\$66,000								
15. Operational support for campaigns: Not applicable									
<p>16. Additional documents to be delivered for future disbursements:</p> <table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or its equivalent.</td> <td>15 May 2015</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent.	15 May 2015				
Reports, documents and other deliverables	Due dates								
Annual Progress Report or its equivalent.	15 May 2015								
17. Financial Clarifications: Not applicable									
18. Other conditions: Not applicable.									

On behalf of Gavi,



Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

LIBERIA ROTAVIRUS VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia						
2. Grant Number: 15-LBR-13b-X / 15-LBR-08b-Y						
3. Date of Decision Letter: 16 December 2014						
4. Date of the Partnership Framework Agreement: 19 August 2013						
5. Programme Title: NVS, Rotavirus Routine						
6. Vaccine type: Rotavirus						
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule						
8. Programme Duration¹: 2015						
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):						
<table border="1"> <thead> <tr> <th></th> <th>2015</th> <th>Total²</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td>US\$941,500</td> <td>US\$941,500</td> </tr> </tbody> </table>		2015	Total ²	Programme Budget (US\$)	US\$941,500	US\$941,500
	2015	Total ²				
Programme Budget (US\$)	US\$941,500	US\$941,500				
10. Vaccine Introduction Grant: US\$139,000 payable up to six months before vaccine introduction.						
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):³						
<table border="1"> <tbody> <tr> <td>Type of supplies to be purchased with Gavi funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of Rotavirus vaccines doses</td> <td>352,500</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td>US\$941,500</td> </tr> </tbody> </table>	Type of supplies to be purchased with Gavi funds in each year	2015	Number of Rotavirus vaccines doses	352,500	Annual Amounts (US\$)	US\$941,500
Type of supplies to be purchased with Gavi funds in each year	2015					
Number of Rotavirus vaccines doses	352,500					
Annual Amounts (US\$)	US\$941,500					
12. Procurement agency: UNICEF						
13. Self-procurement: Not applicable.						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the amount that Gavi has approved.

14. Co-financing obligations: Reference code: 15-LBR-13b-X-C. According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	30,000
Value of vaccine doses (US\$)	US\$73,626
Total Co-Financing Payments (US\$) (including freight)	US\$76,500

15. Operational support for campaigns: Not applicable

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent.	15 May 2015

17. Financial Clarifications: Not applicable

18. Other conditions: Not applicable.

On behalf of Gavi,



Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

LIBERIA YELLOW FEVER VACCINE SUPPORT
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia			
2. Grant Number: 0715-LBR-06b-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 19 August 2013			
5. Programme Title: NVS, Yellow Fever Routine			
6. Vaccine type: Yellow Fever			
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 dose(s) per vial, LYOPHILISED			
8. Programme Duration¹: 2001- 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2001-2014	2015	Total ²
Programme Budget (US\$)	US\$1,550,308 ³	US\$179,000	US\$1,729,308
10. Vaccine Introduction Grant: Not applicable.			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2001-2014	2015	
Number of Yellow Fever vaccines doses		157,900	
Number of AD syringes		160,800	
Number of re-constitution syringes		21,400	
Number of safety boxes		2,025	
Annual Amounts (US\$)	US\$1,550,308 ⁵	US\$179,000	
12. Procurement agency: UNICEF.			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable									
14. Co-financing obligations: Reference code: 0715-LBR-06b-X-C									
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.									
<table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of vaccine doses</td> <td>36,400</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$36,396</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$39,000</td> </tr> </table>	Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	36,400	Value of vaccine doses (US\$)	US\$36,396	Total Co-Financing Payments (US\$) (including freight)	US\$39,000	
Type of supplies to be purchased with Country funds in each year	2015								
Number of vaccine doses	36,400								
Value of vaccine doses (US\$)	US\$36,396								
Total Co-Financing Payments (US\$) (including freight)	US\$39,000								
15. Operational support for campaigns: Not applicable									
16. Additional documents to be delivered for future disbursements:									
<table border="1"> <tr> <td>Reports, documents and other deliverables</td> <td>Due dates</td> </tr> <tr> <td>Annual Progress Report or its equivalent.</td> <td>At a date agreed with Gavi Secretariat.</td> </tr> </table>	Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.					
Reports, documents and other deliverables	Due dates								
Annual Progress Report or its equivalent.	At a date agreed with Gavi Secretariat.								
17. Financial Clarifications: The Country shall provide the following clarifications to Gavi: Not applicable.									
18. Other conditions:									
There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.									

On behalf of Gavi,



Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014